Quarterly report [Sections 13 or 15(d)]

SCHEDULE OF SEGMENT INFORMATION (Details)

v3.25.0.1
SCHEDULE OF SEGMENT INFORMATION (Details) - USD ($)
$ in Thousands
 3 Months Ended
Jan. 31, 2025
Jan. 31, 2024
Oct. 31, 2024
Segment Reporting Information [Line Items]      
Net income (loss) $ (3,213) $ (3,290)  
Total operating costs and expenses 3,386 3,609  
Less non-cash stock-based compensation (1,055) (1,260)  
Operating costs and expenses excluding non-cash share based compensation 2,331 2,349  
Total assets 18,906   $ 21,591
Cancer Vaccines [Member]      
Segment Reporting Information [Line Items]      
Net income (loss) (2,018) (1,756)  
Operating costs and expenses excluding non-cash share based compensation 1,467 1,213  
Total assets 11,863   12,917
CAR-T Therapeutics [Member]      
Segment Reporting Information [Line Items]      
Net income (loss) (1,177) (1,525)  
Operating costs and expenses excluding non-cash share based compensation 848 1,128  
Total assets 6,885   8,535
Other [Member]      
Segment Reporting Information [Line Items]      
Net income (loss) (18) (9)  
Operating costs and expenses excluding non-cash share based compensation 16 $ 8  
Total assets $ 158   $ 139